🌟 Discover the science behind innovation 🌟 We at CatalYm are at the forefront of pioneering a novel cancer therapy approach, leveraging our scientific insights into the newly identified role of GDF-15 as a key regulator of tumor resistance. In the short video below, our Chief Scientific Officer, Christine Schuberth-Wagner, delves into GDF-15’s diverse mechanisms of action in regulating anti-tumor immune responses and driving treatment-induced side effects such as anorexia, nausea, and emesis. She emphasizes the potential of neutralizing this immunosuppressive cytokine as a promising strategy to combat treatment resistance and enhance the clinical outcomes and tolerability of various standard-of-care regimens. Curious to learn more about the science behind our innovative treatment strategy and our clinical lead candidate, visugromab, a GDF-15-targeting antibody? Visit us at www.catalym.com. Stay connected with us on LinkedIn for the latest updates on our lead program, study data, and the next steps on our clinical development journey! #CancerTherapy #GDF15 #Immunotherapy #ClinicalDevelopment
CatalYm GmbH
Biotechnologieforschung
Martinsried, Bayern 3.019 Follower:innen
Developing innovative immunotherapies to transform cancer patients’ lives by engaging their own immune systems.
Info
- Website
-
http://www.catalym.com
Externer Link zu CatalYm GmbH
- Branche
- Biotechnologieforschung
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Martinsried, Bayern
- Art
- Privatunternehmen
Orte
-
Primär
Am Klopferspitz 19
Martinsried, Bayern 82152, DE
Beschäftigte von CatalYm GmbH
Updates
-
Thank you Thorsten Ross for the great representation of CatalYm at the recent Federation of American Societies for Experimental Biology (FASEB)'s Scientific Research Conference!
Looking back at my talk at the Federation of American Societies for Experimental Biology (FASEB)’s Scientific Research Conference on the TGF-beta Superfamily last Monday, I truly enjoyed the fruitful discussions and exchanges it sparked with other experts in the field. It was a pleasure to meet our collaborators and to be joined by my esteemed colleague and fellow GDF-15 enthusiast, María Cecilia González. Our results highlight the importance of GDF-15 as a central mediator of #cancer treatment resistance to platinum-based #chemotherapy. We showed that GDF-15 blockade induced anti-tumor-responses in preclinical tumor models resistant to chemoimmunotherapy treatment, rendering them sensitive again, resulting in tumor growth inhibition and prolonged animal survival. Mechanistically, we demonstrated that GDF-15 neutralization was associated with enhanced activation and proliferation of circulating CD4+ and CD8+ T cells and increased proportions of antigen-presenting dendritic cells in the tumor microenvironment. In addition, we confirmed that GDF-15 expression in tumor cells is induced by chemotherapies like cisplatin, carboplatin and pemetrexed, and that platinum further induces rapid systemic release of GDF-15 from non-malignant cells in vivo limiting tolerability of this treatment regimen. Collectively, our findings further underline the clinical potential of our GDF-15-neutralizing strategy with our lead antibody candidate, visugromab, to counteract the establishment of primary and secondary resistance. Since the combination of platinum-based chemotherapy and PD-(L)1 inhibitors is a central part of the first-line treatment of advanced #NSCLC, our approach may improve the effectiveness and tolerability of standard-of-care treatment in this indication, where a significant proportion of patients still do not respond or experience relapse. If you are curious to learn more about our lead program, which is currently evaluated in a Phase 2 #ClinicalTrial, please visit www.catalym.com. #TGFSRC
-
-
Great news from CatalYm: we have successfully completed an oversubscribed $150 million Series D #financing to advance our lead program #visugromab into randomized Phase 2b clinical trials. This investment will expand visugromab’s late-stage clinical development into earlier lines of treatment including checkpoint naïve and second-line refractory settings in select #SolidTumor indications. We extend a warm welcome to our new investors: Canaan, Bioqube Ventures, Omega Funds, Forbion Growth Fund and Gilde Healthcare Partners. Together with support from our participating existing investors JEITO, Brandon Capital, Novartis Venture Fund and Vesalius Biocapital III the funding highlights the potential of visugromab to bring benefit to cancer patients and also values the novel approach of neutralizing GDF-15, a key resistance factor to anti-cancer therapies. Visugromab is a humanized monoclonal antibody targeting GDF-15, a key regulator of immune resistance to #cancer therapies. Our lead candidate has shown impressive results in a recent Phase 1/2a data update presented at #ASCO2024. The results demonstrated that the combination of visugromab and the PD-1 inhibitor nivolumab achieves deep and durable anti-tumor activity, including complete responses, in patients with anti-PD-(L)1 relapsed/refractory solid tumors. Along with the financing, Colleen Feriod Cuffaro, Partner at Canaan, Jon Edwards, Managing Partner at Bioqube Ventures, and Otello Stampacchia, Managing Director and Founder at Omega Funds, will join our Board of Directors, and Stefan Luzi, PhD, Partner at Gilde joins as an Observer. As we enter this next stage of corporate growth, we remain committed to our mission of breaking immunosuppressive barriers and establishing a new benchmark in cancer care. For more details on the financing, visit: https://lnkd.in/dBfHK4sU
-
Our VP Preclinical Development & Translation Strategy, Thorsten Ross, is looking forward to his presentation next week at the Federation of American Societies for Experimental Biology (FASEB)’s Scientific Research Conference focusing on the TGF-β Superfamily. In his talk on July 22, he will outline our latest findings demonstrating that GDF-15, a member of this cytokine family, is a central mediator of #cancer treatment resistance and toxicity in platinum-based #chemotherapy, which is commonly used alongside PD-1 checkpoint inhibitors in the first-line treatment of advanced #NSCLC. Our preclinical findings showcase the potential of our lead antibody candidate visugromab, a first-in-class GDF-15-blocking antibody, to enhance responses and tolerability of standard-of-care chemoimmunotherapy. Find the full agenda details here https://bit.ly/45Z5aD1 and learn more about our novel strategy to counteract resistance and improve #SolidTumor #patient outcomes at www.catalym.com #TGFSRC
-
-
This weekend, the Coordinating Investigator of our "GDFATHER" Phase 1/2a trial, Prof. Ignacio Melero, MD, PhD, presented compelling new follow-up data at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results highlight that visugromab+nivolumab treatment achieves remarkable deep and durable anti-tumoral activity including multiple complete responses in late- to last-line patients with metastatic non-sq NSCLC, Urothelial cancer and HCC. Currently, median duration of response is surpassing 15 months for NSCLC and 14 months for UC cohorts, with 77% of all responses still ongoing. Remarkably, 53% of patients experiencing a response on study achieved a RECIST 1.1 response level not reached with their initial checkpoint inhibitor treatment in 1L/2L. 75% of the complete responses in non-sq NSCLC and UC had not achieved a CR on any prior systemic treatment before, all ongoing as of now. Patients that entered the trial had to be truly anti-PD-1/PD-L1 relapsed/refractory as per strict criteria. Given the clinical and preclinical data to date, we are convinced that targeting GDF-15 has the potential to break a critical therapeutic resistance pathway and establish a new benchmark in checkpoint inhibition potentiation. We will now take this promising therapeutic concept into 1L and 2L treatment of multiple solid tumor types to maximize potential benefit to patients in need suffering from metastatic solid tumors with no curative option so far. Read more about the full data, the main differentiators of this approach, future development plans, and the potential beneficial impact for patients here: https://lnkd.in/dYwxKq7d
-
-
Are you attending the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting? On Sunday, June 2, at 11:30 AM CDT in the "Developmental Therapeutics-Immunotherapy" session, our Coordinating Investigator, Prof. Ignacio Melero, MD, PhD, will present positive new Phase 2a follow-up data on our GDF-15 neutralizing antibody, visugromab, in advanced #NSCLC, urothelial, and hepatocellular #cancer. Find out more about our upcoming presentation: https://bit.ly/4bPKtei & learn more about how we aim to address GDF-15-mediated #TherapyResistance, one of the major hurdles in cancer treatment, at www.catalym.com #cancerresearch #ASCO2024 #ASCO
-
Our team just returned from the great annual Investigator meeting #IM2024 in Malaga/Spain, where we reviewed the latest data of our #GDFATHER_1_2a and the #GDFATHER_NEO trials. We experienced an exciting meeting and saw great enthusiam for the #visugromab program among our Investigators and the clinical trial staff our our Investigational sites. The meeting circled around latest data updates (with a growing number of complete responses in late to last-line solid tumor patients that in majority had not experienced a CR under any prior treatment), GCP and drug safety trainings and clinical operations insights reg data cleaning and managing 52.000+ eCRF pages. Phantastic educational sessions by Patrizia Giannatempo/Milan (thanks!!!) and Martin Schuler/Essen (thanks!!!) on recent advances in UC and NSCLC treatment rounded up the meeting well. Thanks to all participants for the great meeting and their dedication to bring a novel immunotherapy concept to cancer patients in need! More to come soon with our oral presentation at #ASCO2024 in Chicago by Ignacio Melero on Sunday, June 2nd! See here: https://lnkd.in/de6Wj9si #visugromab #GDF15 #GDFATHER #potentiating_Checkpoint_inhibitor_activity #IM2024 #operationalexcellence #ASCO2024 #IO_therapy #Catalym
-
-
Are you attending the Immuno by Oxford Global Conference (Immuno 2024) starting on Thursday in #London? Don’t miss out on the presentation by our VP Preclinical Research & Translation Strategy, Thorsten Ross , on April 26. He will speak about the role of GDF-15 in #cancer therapy resistance and how blocking GDF-15 can boost current standard-of-care and emerging treatments & improve #patient outcomes. The talk includes recent insights about our lead candidate visugromab, a first-in-class GDF-15-neutralizing antibody, currently being evaluated in Phase 2 clinical trials. Download the full conference program here https://bit.ly/3UhM5I6 & learn more about our novel approach to tackling cancer resistance at www.catalym.com #OGImmuno #Immuno24
-
-
We're proud to share an article by Drug Target Review featuring our Chief Scientific Officer, Dr. Christine Schuberth-Wagner . With over a decade of experience in the field of immuno-oncology and drug discovery, Christine’s achievements are a testament to the impactful contributions of #WomenInSTEM and we are thankful to have her on our team. Learn about Christine's professional journey and her thoughts on both challenges and opportunities unique to women in STEM in the article below. #WomenInScience #Immunooncology #DrugDiscovery #Biotech
🔊 Latest article! 👩🏻🔬Women in STEM with Dr Christine Schuberth-Wagner Dr Christine Schuberth-Wagner serves as Chief Scientific Officer at CatalYm GmbH. She joined the company in November 2018 with more than 10 years of experience in drug discovery and non-clinical development of immunomodulatory drugs in the immuno-oncology space. She has established a track record as a successful leader and entrepreneur in the biotech industry. Prior to joining CatalYm, Christine co-founded Rigontec in 2014 where she led the company’s discovery and non-clinical development activities as Senior Vice President, Research. Her discoveries on the first-in-class RNA-based innate immune receptor agonist RGT100, built the foundation for the initiation of a Phase I clinical trial as well as the successful acquisition of Rigontec by MSD (known as Merck & Co. in North America) in late 2017. Christine holds a PhD in Molecular Biomedicine from the University of Bonn and an MBA from the University of Potsdam. Click the link in the comments to read more! 👇 #womeninSTEM #immunooncology #drugdiscovery
-
-
Listen in to our CSO Christine Schuberth-Wagner together with Roy Baynes
Our latest podcast episode is officially live! Listen to our discussion on 'Breaking resistance: the future of immunotherapy in oncology.' Molecular Devices 🌟 Tune in as we explore the fascinating topic of checkpoint inhibitors in cancer therapy, uncovering how resistance challenges persist and impact clinical success across various cancer types. 🩺💡 We will also be discussing the current landscape and explore potential solutions to this pivotal obstacle in oncology. Featuring insightful perspectives from Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, and Roy Baynes, Chief Scientific Officer at Eikon Therapeutics. Don't miss out, listen now: https://bit.ly/3J5zwcA #podcast #immunotherapy #oncology #science #healthcare
-